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Understanding the molecular mechanisms underlying liver ﬁbro-
genesis is fundamentally relevant to developing new treatments
that are independent of the underlying etiology. The increasing
success of antiviral treatments in blocking or reversing the ﬁbro-
genic progression of chronic liver disease has unearthed vital
information about the natural history of ﬁbrosis regression, and
has established important principles and targets for antiﬁbrotic
drugs. Although antiﬁbrotic activity has been demonstrated for
many compounds in vitro and in animal models, none has been
thoroughly validated in the clinic or commercialized as a therapy
for ﬁbrosis. In addition, it is likely that combination therapies that
affect two or more key pathogenic targets and/or pathways will be
needed. To accelerate the preclinical development of these combi-
nation therapies, reliable single target validation is necessary, fol-
lowed by the rational selection and systematic testing of
combination approaches. Improved noninvasive tools for the
assessment of ﬁbrosis content, ﬁbrogenesis and ﬁbrolysis must
accompany in vivo validation in experimental ﬁbrosis models,
and especially in clinical trials. The rapidly changing landscape
of clinical trial design for liver disease is recognized by regulatory
agencies in the United States (FDA) and Western Europe (EMA),
who are working together with the broad range of stakeholders
to standardize approaches to testing antiﬁbrotic drugs in cohorts
of patients with chronic liver diseases.
 2015 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver. Open access under 
CC BY-NC-ND license.Introduction
After acute injury, the liver can restore its complete mass and ori-
ginal architecture in a relatively short interval even when a largeJournal of Hepatology 20
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E-mail address: m.pinzani@ucl.ac.uk (M. Pinzani).fraction of the organ is destroyed. In contrast, chronic liver injury,
as triggered by different etiologies, induces repetitive tissue dam-
age, resulting in impaired regenerative capacity marked by an
altered inﬂammatory inﬁltrate and a chronic wound healing
response [1,2]. The response to chronic injury also includes
necrosis and/or apoptosis of parenchymal cells and their replace-
ment by extracellular matrix (ECM). Although initially beneﬁcial,
the wound healing process becomes pathogenic if it progressively
replaces parenchyma with scar tissue and distorts the liver vas-
cular architecture, eventually resulting in organ dysfunction.
To date, speciﬁc therapies for liver disease have primarily
been etiology-driven by eliminating or ameliorating the causative
agent of chronic liver diseases (CLD). Recent examples are the
spectacular successes in blocking replication and/or curing
chronic hepatitis B and C virus infections, which have built upon
molecular insights into cellular infection and viral replication.
These strategies have been fruitful in blocking liver injury and
thus progression of ﬁbrosis, and even in reversing advanced
ﬁbrosis. However, ﬁndings in both human studies and animal
models nicely emphasize that liver ﬁbrosis is a dynamic process
that can be modulated either by halting progression and/or
promoting resolution. Thus, the clariﬁcation of molecular
mechanisms underlying these events is fundamentally important
for establishing antiﬁbrotic therapies. The increasing success of
antiviral treatments in blocking or reversing the ﬁbrogenic pro-
gression of CLD has unearthed vital information about the natural
history of ﬁbrosis regression, and has established important prin-
ciples and targets for antiﬁbrotic drugs.Pathophysiology: established and emerging mechanisms
The progression and resolution of ﬁbrosis is a complex process
involving parenchymal and non-parenchymal liver cells, as well
as inﬁltrating immune cells. Chronic hepatocyte death via
apoptosis, necrosis or necroptosis is a critical step. Cell death
induces activation of inﬂammatory and pro-ﬁbrogenic pathways
in non-parenchymal cells and inﬁltrating immune cells, which
trigger ﬁbrosis progression, but may also contribute to ﬁbrosis
resolution [1–3].
The ﬁbrogenic response, as characterized by scar formation
due to increased production and deposition of ECM proteins, is15 vol. 62 j S15–S24
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the essential step that culminates in major changes in liver
architecture. Modiﬁcations in ECM composition and content not
only have mechanical and physical consequences, but also
contribute to the modulation of cellular functions such as growth,
migration, and gene expression, in part through the direct inter-
action between ECM components and cell adhesion molecules.
The ECM also functions as a reservoir for pro-inﬂammatory and
pro-ﬁbrogenic mediators [4].
The key ﬁbrogenic effector cell type in the liver is the activated
hepatic stellate cell (HSC), although other cells and processes can
make signiﬁcant contributions. HSCs are characterized by the
ability to store retinyl esters in intracytoplasmic lipid droplets,
and by ultrastructural features of vascular pericytes consistent
with their role in regulating sinusoidal blood ﬂow [5]. The features
of HSC activation and their phenotypic transformation into
myoﬁbroblasts, as well as their pro-ﬁbrogenic role, have been
extensively clariﬁed and represent an important basis for the
understanding of hepatic ﬁbrogenesis [1–4]. The transition of
HSCs into myoﬁbroblasts is regulated by their interaction with
several cell types and the activation of speciﬁc pathways that
are framed within the context of the wound healing reaction
(Fig. 1). Besides injured hepatocytes, hepatic macrophages,
endothelial cells, and lymphocytes drive HSC activation. The deathHepatic stellate 
cell (HSC)
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Fig. 1. Macrophages are the fuel and brake of liver ﬁbrosis progression and
resolution. The cartoon illustrates the interplay between macrophages and
hepatic stellate cells (HSCs) during liver ﬁbrosis progression and resolution. Acute
or chronic hepatocyte injury triggers the recruitment of inﬂammatory (Ly6Chi)
macrophages into the liver. Persistently activated Ly6Chi macrophages during
chronic injury are a driving force via soluble factors e.g. growth factor, cytokine
and chemokine to induce the transition of resting HSCs into activated HSCs
(myoﬁbroblasts; MFBs). MFBs continuously produce extracellular matrix (ECM)
leading to liver scarring. If chronic injury can be stopped e.g. by eliminating HCV,
macrophages will change their phenotype from an inﬂammatory to a pro-
resolution Ly6Clow phenotype. Ly6Clow macrophages lose their ability to stimulate
and maintain the MFB phenotype. As a consequence MFBs either revert to HSCs or
die from apoptotic cell death. ECM production is stopped and over time ECM is
resolved.
S16 Journal of Hepatology 201of hepatocytes leads to the release of cellular contents (e.g. DNA
and damage-associated molecular patterns known as DAMPs)
and reactive oxygen species that activate resident macrophages
(Kupffer cells) to release pro-inﬂammatory factors like TNFa, IL-
1b, and IL-6, and pro-ﬁbrogenic factors, especially TGFb.
Additional pro-inﬂammatory factors include chemokines like
CCL2, as well as gut-derived pathogen-associated molecular
patterns (PAMPs). An example is the activation of toll-like recep-
tor 4 (TLR4) that leads to repression of the activin membrane
bound inhibitor BAMBI, which further enhances TGFb-dependent
HSC activation [6,7].
In addition to chronic wound healing, oxidative stress
contributes to all ﬁbrogenic disorders characterized by chronic
tissue damage, and to the overexpression of critical genes related
to extracellular matrix remodeling and inﬂammation [8].
Oxidative stress resulting from the activity of free radicals, as
well as by decreased efﬁciency of antioxidant defenses is not
simply a toxic consequence of chronic tissue injury, but rather
actively contributes to excessive tissue remodeling and
ﬁbrogenesis, especially in alcoholic hepatitis and non-alcoholic
steatohepatitis (NASH) [9].
More recently, attention is progressively shifting towards the
pro-ﬁbrotic microenvironment of the liver, with increasing
interest in the role of immune cells, and especially subsets of
macrophages, in regulating the progression or the regression of
ﬁbrosis (Fig. 1) [10]. During acute injury, Kupffer cells (hepatic
macrophages) coordinate the regenerative response. However,
during chronic injury, Kupffer cells drive ﬁbrosis progression,
since they not only activate HSCs but also stimulate the inﬂux of
bone marrow derived immune cells via release of CCL2 and
CCL5 [10]. Thus, the recruitment of immature monocyte-derived
Ly6Chi macrophages is dependent on CCL2 secreted by Kupffer
cells and HSCs [11,12]. In murine models, Ly6Chi macrophages
promote ﬁbrosis progression because their deletion (e.g. in
Cd11b-DTR transgenic mice), inhibits the pro-ﬁbrogenic response
in a model of carbon tetrachloride (CCl4) induced ﬁbrosis. Hence,
immature Ly6Chi CD11b+F4/80+ macrophages and their CCL2-
dependent accumulation are a central mechanism of ﬁbrosis
activation and progression [13]. However, inﬂammatory and
pro-ﬁbrogenic Ly6Chi macrophages can differentiate into
pro-resolution (restorative) Ly6Clo macrophages. Pathways
underlying this switch are of intense interest, because they con-
vert the ﬁbrogenic microenvironment to one that promotes
resolution of liver ﬁbrosis. The fractalkine receptor CX3CR1 may
be a key pathwaymediating this switch, because its greater abun-
dance is associated with a pro-resolution Ly6Clo macrophage
phenotype [14]. While the switch of the less mature pro-inﬂam-
matory Ly6Chi to the mature pro-resolution Ly6Clo macrophage
is therapeutically appealing, it has proven difﬁcult to accomplish
in vivo. Ly6Clo macrophages secrete larger quantities of candidate
ﬁbrolytic matrixmetalloproteinases such asMMP-9 andMMP-13,
and the anti-inﬂammatory cytokine IL-10, which are all implicat-
ed in ﬁbrosis resolution. The relevance of this concept has been
supported by the ﬁnding that transfer of restorative Ly6Clo macro-
phages reduces liver scarring in CCl4-induced liver ﬁbrosis.
Other major areas of development include the role of intesti-
nal microbiota [15,16], the role of tissue hypoxia [17] with the
establishment of an anaerobic pro-inﬂammatory environment
[18], the inﬂuence of epigenetic modiﬁcation in conditioning
the progression of ﬁbrosis [19] and the weight of tissue stiffness
on the progression of the ﬁbrogenic process [20].5 vol. 62 j S15–S24
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Fibrosis reversibility: the ultimate target
The prospect of ﬁbrosis reversibility is striking, and trials using
antiviral drugs have established a clear proof of concept for this
possibility in humans. Animal models have identiﬁed HSCs as
an important molecular target. Gliotoxin administration
speciﬁcally induces apoptosis of HSCs to reverse ﬁbrosis in vivo.
Recent studies employing fate tracing experiments to monitor
the plasticity of HSCs have improved our understanding of HSC
behavior in vivo during ﬁbrosis resolution. HSCs, following their
activation to myoﬁbroblasts, can revert to an inactivated, albeit
not fully quiescent, state [21]. During ﬁbrosis resolution some
myoﬁbroblasts revert into inactivated HSCs, while the remaining
myoﬁbroblasts are triggered to become apoptotic – the fraction
of HSCs that follow each of these fates is not yet clear. Most likely,
the lack of pro-survival signals in a non-ﬁbrogenic liver environ-
ment contributes to HSC reversion or apoptosis, however the
master switches to push myoﬁbroblasts towards HSC reversion
or death are not known either. Interestingly, reverted HSCs are
more prone to myoﬁbroblast transdifferention after subsequent
pro-ﬁbrogenic insults, indicating that a previously injured liver
is more susceptible for new insults because ‘inactivated’ HSCs
are more easily re-activated to become ﬁbrogenic. Despite the
documented evidence of ﬁbrosis and cirrhosis regression in
animal models and the reabsorption of scar tissue following an
effective primary treatment in humans (i.e. sustained viral
response, abstinence from alcohol etc.), the full reversibility of
ﬁbrosis in patients with CLD for 30 years or more is still debated.
Indeed, at advanced stages of the disease, scar tissue is marked by
extensive collagen cross-linking, with a greater presence of elas-
tin, dense acellular/paucicellular ECM, and decreased expression
and/or activity of speciﬁc metalloproteinases [22,23]. In addition,
long-term ﬁbrogenesis in human CLD is characterized by a pro-
gressive resistance to apoptosis of HSC/myoﬁbroblasts, leaving
a critical mass of pro-ﬁbrogenic cells refractory to reversion back
to a quiescent state [24].
More recent research has focused on the biochemical changes
affecting ﬁbrosis irreversibility. An important advance has been
the identiﬁcation of lysyl oxidase 2 (LOXL2) in catalyzing the
cross-linking of extracellular collagens [25]. LOXL2 stabilizes
the ECM, and in more advanced stages reduces ﬁbrosis reversibil-
ity. Therefore, advanced liver cirrhosis may become increasingly
irreversible, but we do not know if there exists a critical point
of virtual irreversibility. Moreover, future new treatment options
will eventually demonstrate to what extent we can reverse
cirrhosis therapeutically.Target selection, multicellular approach and combination
therapy
Activated HSCs, (portal) myoﬁbroblasts and the ECM that they
produce are primary targets of antiﬁbrotic therapies. However,
HSC and myoﬁbroblasts communicate with numerous other cell
types that can promote their ﬁbrogenic activation, induce their
quiescence and apoptosis, or remove excess ECM via release of
ﬁbrolytic enzymes and phagocytosis; together these represent
additional, complementary pharmacological targets. Agents that
target HSC, myoﬁbroblasts and the ECM are ‘direct antiﬁbrotics’,
whereas therapies that address the other cells and pathways are
‘indirect antiﬁbrotics’.Journal of Hepatology 201For devising antiﬁbrotic therapies it is useful to consider two
major multicellular functional units that contribute to ﬁbrosis
with a varying extent, depending on the etiology of liver disease
and its stage: 1) perisinusoidal/vascular – with pericytes, i.e. HSC,
sinusoidal endothelial cells, macrophages/Kupffer cells, other
inﬂammatory cells, and hepatocytes; 2) portal/periportal – with
cholangiocytes/ductular cells, portal ﬁbroblasts and myoﬁbrob-
lasts, and various inﬂammatory cells; this unit also includes a
stromal inﬂammatory compartment – with ﬁbroblasts and
myoﬁbroblasts, T and B cells, and macrophages/dendritic cells
[26–28].
The cellular interactions within these units also deﬁne a
spectrum of growth factors, cytokines, and proteases that serve
as targets for antiﬁbrotic therapies (Fig. 2). In ﬁbrosis, the cellular
interaction within and between these multicellular units is
skewed towards a chronic wound healing response by excess
deposition of scar tissue and vascular remodeling, a default
mechanism that is aimed at maintaining tissue integrity under
continuing (inﬂammatory) injury, at the expense of functional
parenchymal tissue. Notably, even advanced ﬁbrosis/cirrhosis
can reverse to a normal liver architecture when the injury is
eliminated, as has been shown impressively in patients on effec-
tive treatment of chronic hepatitis B and C [29,30]. This process is
too slow for many patients with advanced ﬁbrosis and often no
causal therapy is available, necessitating the development of
antiﬁbrotic therapies that are both effective and free of side
effects. Such therapies should carefully modulate the multicellu-
lar units towards ﬁbrolysis and direct them towards the original
set-point of non-ﬁbrotic tissue maintenance. To this end combi-
nation therapies that address two or more key cellular or molecu-
lar players and/or pathways will be needed.
With the current tools of drug development and validation it
is difﬁcult to realize such a combination approach. First, safety
and efﬁcacy testing of a single agent, even with an optimal biop-
sy-based study design, will require several hundred patients, last
many years and be very costly, with a signiﬁcant risk of failure
[31]. Second, the combination of two agents with proven efﬁcacy
and safety would require another round of clinical validation.
Third, different companies may rather prefer to develop and mar-
ket a monotherapy with limited but proven efﬁcacy than invest-
ing a huge additional effort in validating a promising
combination therapy, especially when the second drug is owned
by another company. A more optimistic view, however, could
envision a paradigm similar to cancer therapeutics, where
combination therapies and cooperation among commercial
stakeholders have become the rule rather than the exception.
To accelerate the preclinical development of potent antiﬁ-
brotic combination therapies, a reliable single target validation
is necessary, followed by a rational selection and testing of
combination approaches. Improved noninvasive tools for the
assessment of ﬁbrosis content, ﬁbrogenesis and ﬁbrolysis must
accompany in vivo validation in experimental ﬁbrosis models,
and especially in clinical trials. Therefore, a top priority is the
development of biomarkers that can be determined frequently
during the course of a treatment (serum parameters and/or imag-
ing) and that truly reﬂect the underlying pathogenesis that is tar-
geted by medications [26,27,31–35]. In liver ﬁbrosis, such
markers would quantify the extent of ﬁbrogenesis and/or ﬁbroly-
sis (ECM deposition and removal, respectively) before and during
treatment, and permit an individualized dose adjustment of a
mono- or combination therapy. Moreover, under the assumption5 vol. 62 j S15–S24 S17
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Fig. 2. Targeting the multicellular context of ﬁbrosis.Major functional units and secreted factors to be addressed by antiﬁbrotic therapies. (A) Vascular and (B) biliary and
interstitial unit. Pro-ﬁbrogenic targets are underlined, in contrast to putative ﬁbrolysis-inducing targets in italics and red. Select examples are discussed in the text.
Modiﬁed from [26–28]. CCL, CC chemokine ligand; CTGF, connective tissue growth factor; CXCL, CXC chemokine ligand; ET-1, endothelin-1; HGF, hepatocyte growth factor;
IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; MMP, matrix metalloproteinase; NO, nitric oxide; PDGF-BB, platelet-derived growth factor BB (recent data
show that most of PDGF-BB in liver ﬁbrosis derives from activated platelets [38]); ROS, reactive oxygen species; TNFa, tumor necrosis factor a; Shh, sonic hedgehog; TGFb1,
transforming growth factor beta1; Th, T helper cell; TIMP, tissue inhibitor of metalloproteinases; TRAIL, TNF-related apoptosis-inducing ligand; Treg, regulatory T cell.
Reviewthat the level of the serum marker or the intensity of the imaging
signal over time correlates with the ﬁnal extent of ﬁbrosis, the
stratiﬁcation of patients could be improved, and the needed
number to be tested and the duration of clinical studies reduced
dramatically. Such biomarkers ideally should correlate with the
effects on morbidity and mortality due to decompensated cirrho-
sis or HCC. Finally, such markers could pave the way for a true
personalized medicine, where different patients might receive
different combinations and doses of antiﬁbrotics, adjusted by
relying on the predictive biomarkers. While there have been
some advances in biomarker development and validation, further
improvement remains a top priority to optimize and guide antiﬁ-
brotic drug development [26,27,32–34]. Notably, the availability
of valid biomarkers of ﬁbrogenesis could establish the antiﬁbrotic
activity of long-used inexpensive and relatively safe medications,
such as statins [36], or aspirin, which prevents the release of pro-
ﬁbrogenic PDGF-BB in models of liver ﬁbrosis progression and
reversal [37]. By targeting different ﬁbrogenic pathways, combi-
nations of repurposed drugs could be more efﬁcient as the side
effect proﬁles would be known, and there would no need for
phase 1 trials to establish safety.Preclinical proof of concept
The antiﬁbrotic effect of a large number of compounds has been
demonstrated in vitro and in animal models of liver ﬁbrosis overS18 Journal of Hepatology 201the past two decades. Numerous compounds seem to have an
adequate safety proﬁle in animal models and in phase 1 clinical
studies, or alternatively the drug is an existing agent used for
other clinical indications, and is re-discovered as an antiﬁbrotic
(‘‘drug repositioning’’) [26,34]. However, none of these
repurposed drugs have been thoroughly validated in the clinic
or commercialized as a therapy for ﬁbrosis. An uncertainty is
the translation of the wealth of information on antiﬁbrotic agents
derived from in vitro and in vivo animal experimental studies into
meaningful advances for patients. A major difﬁculty in translat-
ing animal studies to human diseases is the complexity of the
interactions between cells, soluble mediators, the ECM and its
receptors (i.e. the pro-ﬁbrogenic microenvironment), and intra-
cellular signaling relevant to the ﬁbrogenic process. In this con-
text, most of the information gathered is ‘mono-mechanistical’;
i.e. each study highlights the role of one cell, one cytokine, one
receptor, or one signaling molecule, without considering that
the results obtained are just a very reductionist view of the com-
plex process of hepatic ﬁbrogenesis.
In vitro models
Currently, biologic targets for antiﬁbrotic therapies are identiﬁed
by studies done in 2D monolayer single cell cultures or co-
cultures (activated HSC and other liver cells that contributed to
ﬁbrogenesis or ﬁbrolysis) on plastic dishes followed by a ‘‘valida-
tion’’ in mouse or rat models. In this context, it is important to5 vol. 62 j S15–S24
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highlight that the identiﬁcation of ﬁbrogenic targets following
activation of HSC in 2D monolayer single cell cultures only
partially corresponds to the pattern of target activation found
in animal models of liver ﬁbrogenesis [38]. Drug development
is based on this methodological sequence, and newly developed
drugs are tested on the same in vitro and in vivomodels, and then
often proposed for human use. In part, the current lack of effec-
tive translation is due to the inherent problems associated with
drug evaluation in suboptimal models. For example, 2D cell
cultures of hepatic ﬁbrogenic cells (HSC) exhibit constitutive acti-
vation of a ‘‘myoﬁbroblast-like’’ phenotype following growth on
an artiﬁcial plastic substrate. Importantly, cell culture plastic sur-
faces mimic a tissue tension of 106 kPa compared to tension of
the liver 3D structure, which ranges between 5 (normal liver)
and 20 (ﬁbrotic/cirrhotic liver) KPa [39,40]. Thus, conventional
2D cell culture is suboptimal as a surrogate to test and evaluate
drug targets. The introduction of in vitro systems for target dis-
covery and drug screening that more faithfully replicate the
pro-ﬁbrogenic microenvironment of human liver is greatly await-
ed. These models should at least ensure the presence of a 3D
structure and the expression of a sufﬁcient physiological and
pathophysiological variety of ECM components. Indeed, there is
increasing evidence of the different effect of 2D and 3D ECMs
on key biological features of ﬁbroblasts and myoﬁbroblasts,
including proliferation, migration, contraction, matrix deposition
and degradation [41,42]. Of particular interest is myoﬁbroblast
mechano-function, and different models have been generated to
mimic normal skin, wound repair, tissue morphogenesis and
remodeling, as well as growth and contracture during scarring/
ﬁbrosis [43,44]. Recent data obtained by culturing human HSC in
ECM scaffolds from decellularized human liver tissue have high-
lighted remarkable differences in gene and protein expression of
established pro-ﬁbrogenic agonists/pathways, when compared to
standard 2D cultures on plastic dishes [45]. Accordingly, using 3D
in vitro cultures or co-cultures as an initial methodological step
may be a better initial approach to identify pharmacological
targets. Following in vivo validation in adequate animal models,
bioengineered human 3D ECM scaffolds could then represent the
next step in verifying drug efﬁcacy before testing in human trials.Animal models of liver ﬁbrogenesis
Improved animal models are required to assess antiﬁbrotic
efﬁcacy within the complex multicellular context of disease,
and to study the bioavailability, pharmacokinetics, and toxicity
of candidate antiﬁbrotic agents [33]. Mdr2 KO mice that lack
the hepatocyte phospholipid ﬂippase Mdr2 mimic human prima-
ry sclerosing cholangitis as a model of spontaneous biliary ﬁbro-
sis progression (Mdr2 KO) [46], while administration of toxins
(CCl4 and/or thioacetamide) induces a progressive parenchymal
ﬁbrosis, which after long-term administration, shows little
reversibility if the agent is discontinued [47]. Drugs that work
in multiple models will have a higher likelihood to be effective
in human ﬁbrosis, which is less inﬂammatory and necrotic than
most animal models. Although (mono-) genetic models (e.g.
transgenic mice with overexpression of PDGF-B, PDGF-C, or
TGFb1 [48–50]) can validate factors and mechanisms that are
central to ﬁbrosis, transgene expression in these models is either
largely ectopic (hepatocytes) or disregards regulatory circuits
operative in non-transgenic ﬁbrotic animals. Importantly,
in vivo models should be performed according to standardizedJournal of Hepatology 201guidelines. These include: 1) selection of animals of deﬁned
(adult) age and sex; 2) group sizes of 8–15 animals; 3) optimized
route and dose of toxin application; 4) analysis of liver samples of
sufﬁcient size (5–10% of the organ); 5) representative
morphometric analyses; 6) the use of a representative spectrum
of quantitative ﬁbrosis and ﬁbrolysis readouts [33]. Many
published studies do not satisfy these criteria.
Precision-cut liver slices (PCLS)
Transferability of animal studies to the human situation is uncer-
tain and may vary with the pharmacological target. Human PCLS
are 200 lm thick sections of liver that can be cultured for sev-
eral days and partly reﬂect the multicellular human context [51].
They can be isolated from normal liver resections, which undergo
spontaneous ﬁbrogenic activation in culture, or from cirrhotic liv-
er explants. PCLS can serve as a bridge from animal models to
human translation and can test many different pharmacological
agents, although more studies are needed to fully validate the
technology. Use of human PCLS also may help circumvent
concerns about the differences in inﬂammatory or ﬁbrogenic
pathways between rodents and humans [52].Clinical trials – state of the art and unmet needs
The accelerating progress in understanding mechanisms of hep-
atic ﬁbrosis and deﬁning therapeutic targets has heightened the
urgency to establish clinical trial designs that can accurately
assess efﬁcacy of antiﬁbrotic drugs. Before deﬁning clinical trial
features, however, it is important to understand the dynamics
of ﬁbrosis regression now that effective disease speciﬁc drugs
have been developed for several liver diseases. Importantly,
standard systems of ﬁbrosis staging (e.g. Ishak, Brunt, Metavir)
may not be as accurate as direct collagen proportionate area
quantiﬁcation, which correlates extremely well with clinical out-
comes [53]. Regardless of the morphologic method, sustained
suppression of hepatitis B yields remarkable improvements in
inﬂammation and necrosis within one year, with subsequent
improvement in ﬁbrosis that is demonstrable at ﬁve years
[29,54]. Similarly, effective treatment of hepatitis C also leads
to remarkable ﬁbrosis regression [30,55]. Although published
experience is less extensive than for HBV, more information
about ﬁbrosis regression in chronic hepatitis C is expected now
that highly effective direct acting antiviral drugs are entering
widespread use. Remarkably, cirrhosis as deﬁned by standard
staging criteria is reversible in up to two thirds of patients when
effectively treated with antiviral agents for HBV or HCV
[29,30,54,55]. Emerging data from a trial treating NASH patients
with bariatric surgery suggests remarkably similar patterns of
improvement, with dramatic reductions in NASH activity score
at one year but more modest antiﬁbrotic effects during this inter-
val [56]; longer term follow-up is still pending in these patients,
but continued ﬁbrosis regression is anticipated. In aggregate,
these ﬁndings are important because they establish a realistic
timeframe during which efﬁcacy of an antiﬁbrotic drug can be
detected. Speciﬁcally, while signiﬁcant improvements in necro-
inﬂammation often occur within one year, drugs targeting only
ﬁbrosis will likely take longer to establish their efﬁcacy based
on histologic criteria.
These ﬁndings also underscore the increasing limitations
imposed by reliance on liver biopsy in clinical trials, not only5 vol. 62 j S15–S24 S19
Table 1. Major studies with liver ﬁbrosis as primary or co-primary endpoint. Modiﬁed from [27,68].
Cause Drug name (action), treatment, patients included (F, C, NR, SVR) Efficacy Year of 
completion/
publication
Phase No. of 
patients
NCT
Ref.
HCV (not exclusively 
antiviral agents)
Farglitazar (PPARγ agonist); 52 wk, r, db (F/NR) No effect 2010 2 225/265 [31]
GS-9450 (pan-caspase inhibitor) vs. plac; 24 wk, nr, db (F/NR) No results reported 2010 2 307 00874796
Irbesartan (AT1R antagonist) vs. plac; 2 yr, r, db (F/NR) Pending 2013 3 166 00265642
Fuzheng Huayu (Chinese herbal drug) vs. plac, 48 wk, r, db (F) Pending 2014 2 100 00854087
Pirfenidone (anti-inflammatory) vs. plac, 2-yr intervention Pending 2014 2-3 150 02161952
HBV (not exclusively 
antiviral agents)
Fuzheng Huayu vs. plac; 6 mo, r, db (F); biopsy and serum fibrosis markers Significant for fibrosis regression and fibrosis markers 2005 226 [57]
FG-3019 (anti-CTGF mAb) vs. entecavir vs. plac; 45 wk, r, db (F) Pending 2016 2 228 01217632
Entecavir ± Fuzheng Huayu vs. plac, 48 wk, r, db (C) Pending 2016 4 700 02241590
HBV/HCV, coinfected Oltipraz (Rock-kinase inhibitor) vs. plac; 24 wk, r, db (F,C) No effect 2007/2011 2 83 00956098
PBC UDCA vs. plac; 2 yr, db (F,C) No effect 1991 3 146 [58]
UDCA vs. plac; 4 yr, r, db (F,C) Lower fibrosis progression 2000 4 103 [59]
Obeticholic acid (FXR agonist) vs. plac; 12 mo-8 yr, r, db (F); UE and serum fibrosis markers Pending 2023 3b 350 02308111
Alcoholic hepatitis Candesartan (ACE inhibitor); 6 mo, r, db (F) Significant histological improvement; 33.3% vs. 11.6% 2009/2012 1-2 85 [60]
PSC GS-6624 (anti-LOXL2 mAb) vs. plac; 96 wk, r, db (F) Pending 2015 2 225 01672853
NASH Orlistat (pancreatic lipases inhibitor) vs. 1400 kcal diet (30% fat); 36 wk, r, ol (F) No results reported 2006 4 50 00160407
Pioglitazone (PPARγ agonist) vs. plac; 6 mo, r, db No effect 2006 4 55 [61]
Pioglitazone vs. plac; 1 yr, r, db (F) Decreased fibrosis 2008 - 74 [62]
Pioglitazone vs. Vit E vs. plac; 2 yr, r, db (F) Improved inflammation, in all treatment arms trend for 
decreased fibrosis 
2009-2010 3 247 [63]
Rosiglitazone (PPARγ agonist) vs. plac; 1 and 2 yr, r (F) No effect on fibrosis 2010 - 53 [64]
Pentoxifylline (anti-TNFα) vs. plac; 1 yr, r, db (F) Improved steatosis, inflammation and fibrosis 2010-2011 2 55 [65]
Rosiglitazone (R) vs. R + metformin vs. R + losartan; 48 wk, r, ol (F) No effect on fibrosis 2011 - 137 [66]
High-dose UDCA vs. plac, 1 yr, r, db (F) Significant reduction only of FibroTest 2011 3 126 [67]
Metformin (AMP kinase agonist, anti-diabetic); 1 yr, r, db (F) No results reported 2012 4 80 00134303
Metformin vs. insulin; 1 yr, r, (C) Pending 2016 126 02234440
Liraglutide (GLP-1 agonist) vs. plac; 48 wk, r, db (F) No results reported 2013 2 52 01237119
Pentoxifylline + Vit E vs. Vit E; 3 mo (biopsy), r, db (F) No results reported 2013 3 120 01384578
Losartan (AT1R antagonist) vs. plac; 2 yr, r, db (F)` Pending 2014 3 214 01051219
Obeticholic acid (FXR agonist) vs. plac; 72 wk, r, db (F) Significant for steatosis and inflammation; marginal 
effect on fibrosis
2014 2 280 [68]
Pioglitazone (PPARγ agonist) vs. Vit E vs. plac; 1.5 and 3 yr, r, db (F) Pending 2014 4 90 00994682
GS-6624 (anti-LOXL2 mAb; 75 mg vs. 125 mg) vs. plac; 100 wk, r, db (F) Pending 2015 2 225 01672866 
GS-6624 (200 mg vs. 700 mg) vs. plac; 100 wk, r, db (F,C) Pending 2015 2 225 01672879
GFT505 (dual PPAR α/δ agonist); 52 wk, r, db (F) Pending 2015 2 270 01694849
Pioglitazone (Pio) vs. Vit E vs. Vit E + Pio vs. plac; 1.5 and 3 yr, r, db (F) Pending 2015 4 90 01002547
Vi. D vs. lifestyle counseling; 2 yr, r, ol (F) Pending 2014 3 200 01623024
Vi. D3 vs. plac; 48 wk, r, db (F) Pending 2015 2 60 01571063
Omega-3 (fish oil) vs. plac; 1 yr, r, db (F) No results reported 2010 2/3 64 00681408
Omega-3 (fish oil); 18 mo, r, sb (F) No results reported 2013 2 100 00760513
Docosahexaenoic acid; 2 yr, r, db  (F) No results reported 2011 1/2 60 00885313
Eicosapentaenoic acid vs. plac; 1 yr, r, db (F) No results reported 2012 2 243 01154985
Diamel (dietary supplement) vs. plac vs. lifestyle counseling; 52 wk, r, db (F) No results reported 2012 3 158 00820651
ACE, angiotensin-converting enzyme; AT1R, angiotensin II receptor type 1; C, cirrhosis; CTGF, connective tissue growth factor; db, double-blind; F, ﬁbrosis; IFN, interferon; FXR, farnesoid X receptor; GLP-1, glucagon-like
peptide-1, IL, interleukin; LOXL2, lysyl oxidase-like 2; mAb, monoclonal antibody; NCT, number at ClinicalTrials.gov; NR, non-responders; nr, non-randomized; ol, open-label; r, randomized; retro, retrospective analysis;
TNFa, tumor necrosis factor a; UDCA, ursodeoxycholic acid; UE, ultrasound elastography; Vit, vitamin.
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because of its invasive nature and its propensity to sampling
variability, but also because there may be earlier changes in ﬁbro-
genic activity that may occur earlier than could be detected by
biopsy. To date, however, no noninvasive markers can reliably
detect evidence of an antiﬁbrotic effect, although clinical trials
are already incorporating such exploratory markers as secondary
endpoints.
These obstacles notwithstanding, a remarkable number of
clinical studies with liver ﬁbrosis as primary or co-primary end-
point have been initiated and even concluded. Table 1 highlights
the results of some of these clinical trials [57–68].
Markers of ﬁbrosis and ﬁbrogenic activity
A broad range of noninvasive markers is under intensive study to
complement or replace biopsy in future trials (Table 2). These
include vibration controlled shear wave elastography [69],
magnetic resonance elastography [70], acoustic force radiationTable 2. Potential endpoints for clinical trials.
1. Liver histology
a. Necroinflammation 
i. NAFLD Activity Score
ii. Knodell score
b. Fibrosis
i. Fibrosis staging-Brunt, Metavir, Ishak
ii. Collagen proportionate area
c. Markers of fibrogenic cell activity
i. Alpha smooth muscle actin quantification
ii. Beta PDGF receptor quantification 
2. Liver stiffness
a. Vibration controlled transient elastography
b. Shear wave elastography
c. Acoustic radiation force impulse imaging
d. Magnetic resonance elastography
3. MR or PET-based technologies
a. Liver inflammation score
b. Proton density fat fraction
c. Collagen or lysyl oxidase content using specific contrast agent
d. Receptor binding by PET ligands
4. Serum tests
a. Fibrogenic panels that include ECM molecules
b. Other serum marker panels
i. FIB-4
ii. ELF test
iii. APRI
c. Lipidomic profiles or markers
5. Functional tests
a. Cholate clearance
b. 13C methacetin breath test
c. Indocyanine green clearance tests
d. Galactose elimination tests
e. Collagen synthesis quantification measuring 13C labeled turnover
6. Clinical Scores
a. MELD score
b. Child-Pugh score
c. Maddrey discriminant function (for alcoholic liver disease)
d. Lille Score (for alcoholic liver disease)
e. Combined clinical/pathologic scores (for alcoholic liver disease)
Journal of Hepatology 201impulse force impulse imaging [71], magnetic resonance tech-
niques to determine the inﬂammation and ﬁbrosis score [72] or
that speciﬁcally ﬁnd and quantify ECM molecules [73], dynamic
markers of collagen synthesis using non-radiolabeled isotopes
[74], PET imaging to label ﬁbrosis-speciﬁc cells or receptors
[27], as well as a growing list of functional studies. Such function-
al studies may not directly reﬂect histology, but could be far more
sensitive in determining liver reserve and clinical outcomes,
much as spirometry is a vital endpoint in trials of antiﬁbrotic
drugs for idiopathic pulmonary ﬁbrosis. Functional studies cur-
rently under evaluation include a cholate clearance test which
has been extensively validated in HCV patients [75] as well as a
breath test that assesses the ability of microsomal enzymes to
metabolize a 13C labeled orally administered substrate to release
13CO2 in the nasal breath [76].
In addition to general tests of liver integrity or function, there
may additionally be disease- or drug-speciﬁc tests to establish
proof of target engagement or mechanism. For example, antagon-
ism of a speciﬁc signaling pathway could include patients with
more advanced disease and might rely upon a biomarker that
speciﬁcally reﬂects blockage of the target pathway either in
tissue, by imaging or in blood.
Current concepts of clinical trial design – a rapidly moving target
Despite the limitations of current noninvasive markers, the
urgent need to develop new antiﬁbrotic drugs, combined with
the impressive success of candidate therapies in animal models
demands that trials be initiated without delay while we accrue
further information about noninvasive markers. The rapidly
changing landscape of clinical trial design for liver disease is rec-
ognized by regulatory agencies in the United States (FDA) and
Western Europe (EMA), who are working together with the broad
range of stakeholders to standardize approaches to clinical trial
design. Similar collaborative models of stakeholder engagement
have been successfully employed to accelerate progress in clini-
cal trial design for HIV and HCV [77], and thus optimism prevails
that similar cooperation in standardizing approaches to antiﬁ-
brotic therapies will accelerate progress. Moreover, a series of
consensus conferences and meetings of key opinion leaders is
also contributing to the rapid consolidation of knowledge and
accelerated development of new trial strategies.
At present, NASH is the dominant disease indication for candi-
date antiﬁbrotic drugs. This focus on NASH reﬂects both the
astonishing improvement in the speciﬁc therapies for viral hep-
atitis, combined with the growing appreciation of the magnitude
of the obesity and fatty liver disease epidemics, which affects up
to tenfold more individuals than HCV in the US and Europe.
Moreover, speciﬁc ethnicities are at heightened risk of fatty liver
disease at relatively lower BMIs, including Latin Americans, and
Asians.
Fig. 3 summarizes potential variables for patient stratiﬁcation
in antiﬁbrotic clinical trials. The ﬁrst criterion for clinical trial
design is to clearly deﬁne patients who are at the greatest risk
for disease progression, and to ensure that these risk factors are
equally distributed between placebo and control groups in ran-
domized controlled trials. While genetic factors may contribute
up to 20% of the risk in NASH, at present these genetic factors
cannot be reliably used to stratify risk. Instead, the presence of
diabetes, older age, elevated ALT, and severe BMI elevation are5 vol. 62 j S15–S24 S21
Etiology of liver disease Ethnicity
BMI
Diabetes
Fibrosis progression rate
Histology score
(significant or advanced fibrosis)
Non invasive measures (transient elastography, ARFI,
SWE, MRE, serum markers) and advanced imaging
Patient selection
HVPG
Genetic predisposition (HCV)
Co-factors: alcohol,
metabolic syndrome,
smoking, viral
Age/gender
Fig. 3. Potential variables for patient stratiﬁcation in antiﬁbrotic clinical
trials. ARFI, Acoustic radiation force impulse imaging; BMI, body mass index;
HVPG, hepatic vein pressure gradient; MRE, magnetic resonance elastography,
SWE, shear wave elastography.
Reviewmore prevalent risk factors for progression [78] and must be dis-
tributed equally among study groups in a clinical trial.
An additional element to be used in stratifying patients is the
stage of disease. Drugs that target inﬂammation and cell injury
are likely to be effective at earlier and intermediate stages of
the disease, and thus trials testing these agents might avoid
patients with more advanced ﬁbrotic stages to establish proof
of principle in phase 2 trials. In contrast, drugs targeting mechan-
isms that are more important as disease advances could favor the
enrollment of more advanced patients, which in turn allows the
inclusion of endpoints that reﬂect more advanced disease stages.
These endpoints could include hepatic venous pressure gradient
[79], which correlates strongly with clinical outcomes, as well
as MELD or Child-Pugh scores.
Ultimately, approval of antiﬁbrotic drugs will rely on
endpoints that have either a direct correlation with clinical out-
comes, or are reasonably likely to predict clinical outcomes, since
effective therapies must improve how a patient ‘‘feels, functions,
or survives’’, according to FDA. Thus, endpoints such as hepatic
vein pressure gradient, which reliably correlate with clinical
outcomes, have a special appeal for inclusion in antiﬁbrotic drug
trials.
Following clariﬁcation of enrollment criteria and patient
selection, the next challenge in trial design is whether biomarkers
will be incorporated for interval analysis of efﬁcacy. As noted,
there are no validated noninvasive markers to indicate a drug is
showing efﬁcacy at intermediate time points, so that current trial
designs are likely to rely upon liver biopsy, and would need to be
conducted for at least one year, and preferably longer.
Nonetheless, incorporation of exploratory biomarker assessments
such as imaging and functional tests in the current generation of
clinical trials could lead to their inclusion as primary endpoints
in later trials.
Trial design for liver diseases other than NASH is even more
problematic. In principle, alcoholic liver disease could rely not
only on biopsy, but also recent disease speciﬁc scoring systems
that include clinical and pathologic data [80]. Drug therapy of
this disease is especially challenging because of the confounding
effects of continued alcohol use or its cessation in the midst of a
trial. Even more vexing is primary sclerosing cholangitis, in
which biomarkers of disease and risk factors for progression
are poorly understood. In fact, imaging tests in this disease do
not reliably reﬂect ﬁbrosis, and large duct disease cannot beS22 Journal of Hepatology 201assessed by liver biopsy. Nonetheless, the severity of this disease,
its high propensity to develop cholangiocarcinoma, and the abso-
lute absence of therapies demand intensive efforts to identify
disease speciﬁc biomarkers that can be used as endpoints in clin-
ical trials of anti-inﬂammatory or antiﬁbrotic drugs for this
condition.
In summary, now that there is intense focus on development
and testing of drugs to treat hepatic ﬁbrosis, consolidation and
progress in developing endpoints and clinical trial designs is
imminent. It is anticipated that guidelines in this review will
rapidly become outdated as the ﬁeld extends into prospects for
attenuating CLD that could not have been imagined 30 years
ago when the Journal of Hepatology was launched.Financial support
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